The revolution against cancer that is already here: vaccines against it using covid technology and drug combinations

Recent advancements in oncology include the successful use of mRNA vaccines, similar to those used against Covid-19. At the ESMO Congress, a personalized mRNA vaccine developed by MSD and Moderna showed promising results in a phase III trial, reducing relapse or death risk by 42% in high-risk melanoma patients. Additionally, a new treatment for small cell lung cancer combining tarlatamab and durvalumab was highlighted, marking a significant improvement in survival rates. Experts emphasize the potential of personalized immunotherapy and the need to explore its effectiveness across various cancer types.